Ahmet Seyfeddin Gurbuz1, Semi Ozturk2, Suleyman Cagan Efe3, Mehmet Fatih Yilmaz2, Raziye Ecem Yanik4, Ali Yaman5, Cevat Kirma4. 1. Department of Cardiology, Necmettin Erbakan University Meram Medicine Faculty, Konya, Turkey, ahmetseyfeddingurbuz@hotmail.com. 2. Department of Cardiology, Haseki Training and Research Hospital, Istanbul, Turkey. 3. Department of Cardiology, Istanbul Training and Research Hospital, Istanbul, Turkey. 4. Department of Cardiology, Kartal Kosuyolu Training and Research Hospital, Istanbul, Turkey. 5. Department of Biochemistry, Marmara University School of Medicine, Istanbul, Turkey.
Abstract
OBJECTIVE: Heparanase (HPA), mammalian endo-β-D-glu-cu-ronidase, separates heparan sulfate chains of proteoglycans and changes the structure of the extracellular matrix. We investigated whether serum levels of HPA differ in patients with stable coronary artery disease (SCAD) and subjects with normal coronary arteries. METHODS: This study enrolled 92 patients with SCAD and 34 controls with normal coronary arteries. Levels of HPA were measured by a commercially available human HPA enzyme-linked immunosorbent assay kit. RESULTS: Serum HPA levels were significantly lower in the SCAD group (137.5 [104.1-178.9] vs. 198.8 [178.2-244.9] pg/mL; p < 0.001). Serum HPA levels were significantly higher in subjects with diabetes mellitus (DM) compared to those without DM (p = 0.008). Levels of HPA were lower in the SCAD group, both in the diabetic and nondiabetic subgroups, as compared to controls (p < 0.001 for both subgroups). Levels of HPA positively correlated with fasting blood glucose (FBG) (r: 0.42; p < 0.001). In multiple logistic regression analysis, serum HPA level (odds ratio [OR]: 0.975; 95% confidence interval [CI]: 0.966, 0.985; p < 0.001) and FBG (OR: 1.028; 95% CI: 1.010, 1.047; p = 0.002) were independently associated with SCAD. The receiver operating characteristic curve showed that HPA levels less than 160.6 pg/mL predicted SCAD with 65% sensitivity and 97% specificity (AUC: 0.80; 95% CI: 0.728, 0.878; p < 0.001). CONCLUSION: Diabetes and FBG levels were closely associated with serum levels of HPA. Low serum levels of HPA may predict SCAD in both diabetic and nondiabetic populations.
OBJECTIVE:Heparanase (HPA), mammalian endo-β-D-glu-cu-ronidase, separates heparan sulfate chains of proteoglycans and changes the structure of the extracellular matrix. We investigated whether serum levels of HPA differ in patients with stable coronary artery disease (SCAD) and subjects with normal coronary arteries. METHODS: This study enrolled 92 patients with SCAD and 34 controls with normal coronary arteries. Levels of HPA were measured by a commercially available humanHPA enzyme-linked immunosorbent assay kit. RESULTS: Serum HPA levels were significantly lower in the SCAD group (137.5 [104.1-178.9] vs. 198.8 [178.2-244.9] pg/mL; p < 0.001). Serum HPA levels were significantly higher in subjects with diabetes mellitus (DM) compared to those without DM (p = 0.008). Levels of HPA were lower in the SCAD group, both in the diabetic and nondiabetic subgroups, as compared to controls (p < 0.001 for both subgroups). Levels of HPA positively correlated with fasting blood glucose (FBG) (r: 0.42; p < 0.001). In multiple logistic regression analysis, serum HPA level (odds ratio [OR]: 0.975; 95% confidence interval [CI]: 0.966, 0.985; p < 0.001) and FBG (OR: 1.028; 95% CI: 1.010, 1.047; p = 0.002) were independently associated with SCAD. The receiver operating characteristic curve showed that HPA levels less than 160.6 pg/mL predicted SCAD with 65% sensitivity and 97% specificity (AUC: 0.80; 95% CI: 0.728, 0.878; p < 0.001). CONCLUSION: Diabetes and FBG levels were closely associated with serum levels of HPA. Low serum levels of HPA may predict SCAD in both diabetic and nondiabetic populations.
Authors: Paul Frey; David D Waters; David A DeMicco; Andrei Breazna; Larry Samuels; Andrew Pipe; Chuan-Chuan Wun; Neal L Benowitz Journal: Am J Cardiol Date: 2010-12-02 Impact factor: 2.778
Authors: Aaron B Baker; William J Gibson; Vijaya B Kolachalama; Mordechai Golomb; Laura Indolfi; Christopher Spruell; Eyal Zcharia; Israel Vlodavsky; Elazer R Edelman Journal: J Am Coll Cardiol Date: 2012-04-24 Impact factor: 24.094
Authors: Aaron B Baker; Yiannis S Chatzizisis; Roy Beigel; Michael Jonas; Benjamin V Stone; Ahmet U Coskun; Charles Maynard; Campbell Rogers; Konstantinos C Koskinas; Charles L Feldman; Peter H Stone; Elazer R Edelman Journal: Atherosclerosis Date: 2010-09-18 Impact factor: 5.162
Authors: Emrah Bayam; Macit Kalçık; Ahmet Seyfeddin Gürbüz; Mahmut Yesin; Ahmet Güner; Sabahattin Gündüz; Mustafa Ozan Gürsoy; Süleyman Karakoyun; Sinan Cerşit; Alev Kılıçgedik; Özkan Candan; Ali Yaman; Mehmet Özkan Journal: Thromb Res Date: 2018-09-26 Impact factor: 3.944